ArticleCurrent developments in nutrition2025
Diet and Lifestyle Quality in Australian Females with Endometrial Cancer at Diagnosis: Insights from the Fertility-sparing Management for Early Endometrial Cancer (FeMMe) Trial.
Article in Current developments in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01686126 (A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diet, lifestyle, and body composition may impact quality of life (QoL) and health outcomes in females with endometrial cancer (EC). Many seek guidance on improving prognosis, treatment outcomes, and QoL through nutrition and other modifiable lifestyle factors. Objectives: This study aims to investigate diet and lifestyle quality in FeMMe trial participants and associations with glycemic control, body composition, QoL, and mental health before treatment. Methods: Baseline data from the multicenter, 3-arm, phase II FeMMe trial (NCT01686126), which enrolled females with obesity and early-stage EC or complex endometrial hyperplasia with atypia undergoing conservative hormonal therapy. The Mediterranean diet score (MDS), World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR), and Extended Healthy Lifestyle Index (EHLI) scores were derived from self-reported dietary and lifestyle data. QoL, depression, and anxiety were measured using validated tools. Anthropometry and body composition (height, weight, hip, and waist circumference) were measured by a study nurse. Glycemic control was assessed using blood samples, utilizing the Homeostatic Model Assessment for Insulin Resistance as the measurement metric. Bonferroni correction applied for multiple comparisons; nominal associations defined as Results: Approximately 40.7%, 31.3%, and 34.7% of females had good diet and/or lifestyle quality according to the MDS, WCRF/AICR, and EHLI, respectively. We found that higher WCRF/AICR scores, expressed per standard deviation (SD) increase, were nominally associated with a better overall QoL score ( Conclusions: Among females with EC and BMI ≥ 30 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.